Thapi Dharma相关文献与解析，生知库 | 链接生命科学的每一步

Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition

针对MUC16的双特异性T细胞接合抗体在单药治疗以及与PD-1和VEGF抑制剂联合治疗中均显示出对卵巢癌的疗效。

doi:10.3389/fimmu.2021.663379

Oladapo O Yeku ,Thapi Dharma Rao ,Ian Laster ,Artem Kononenko ,Terence J Purdon ,Pei Wang ,Ziyou Cui ,Hong Liu ,Renier J Brentjens ,David Spriggs

Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies

利用高亲和力抗体靶向半乳糖凝集素 3 来抑制高级别浆液性卵巢癌和其他表达 MUC16/CA-125 的恶性肿瘤

期刊:Scientific Reports

影响因子:3.8

doi:10.1038/s41598-021-82686-3

Marina Stasenko #, Evan Smith #, Oladapo Yeku, Kay J Park, Ian Laster, Kwangkook Lee, Sven Walderich, Elizabeth Spriggs, Bo Rueda, Britta Weigelt, Dmitriy Zamarin, Thapi Dharma Rao, David R Spriggs

Radiopharmacologic screening of antibodies to the unshed ectodomain of MUC16 in ovarian cancer identifies a lead candidate for clinical translation

对卵巢癌中未脱落的 MUC16 胞外域抗体进行放射药理学筛选，确定了临床转化的主要候选药物

期刊:Nuclear Medicine and Biology

影响因子:3.6

doi:10.1016/j.nucmedbio.2020.04.006

Brandon Nemieboka, Sai Kiran Sharma, Thapi Dharma Rao, Kimberly J Edwards, Su Yan, Pei Wang, Ashwin Ragupathi, Alessandra Piersigilli, David R Spriggs, Jason S Lewis

Antibodies Against Specific MUC16 Glycosylation Sites Inhibit Ovarian Cancer Growth

针对特定MUC16糖基化位点的抗体可抑制卵巢癌的生长

期刊:ACS Chemical Biology

影响因子:3.8

doi:10.1021/acschembio.7b00305

Rao, Thapi Dharma; Fernández-Tejada, Alberto; Axelrod, Abram; Rosales, Nestor; Yan, Xiujun; Thapi, Sahityasri; Wang, Amy; Park, Kay J; Nemieboka, Brandon; Xiang, Jingyi; Lewis, Jason S; Olvera, Narciso; Levine, Douglas A; Danishefsky, Samuel J; Spriggs, David R

Structural basis for antibody recognition of the proximal MUC16 ectodomain

抗体识别近端 MUC16 胞外域的结构基础

Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition

针对MUC16的双特异性T细胞接合抗体在单药治疗以及与PD-1和VEGF抑制剂联合治疗中均显示出对卵巢癌的疗效。

Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies

利用高亲和力抗体靶向半乳糖凝集素 3 来抑制高级别浆液性卵巢癌和其他表达 MUC16/CA-125 的恶性肿瘤

Radiopharmacologic screening of antibodies to the unshed ectodomain of MUC16 in ovarian cancer identifies a lead candidate for clinical translation

对卵巢癌中未脱落的 MUC16 胞外域抗体进行放射药理学筛选，确定了临床转化的主要候选药物

Antibodies Against Specific MUC16 Glycosylation Sites Inhibit Ovarian Cancer Growth

针对特定MUC16糖基化位点的抗体可抑制卵巢癌的生长